Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 8, 2009, Pages 1446-1453

  Seliger, Gregor ^a,b   Mueller, Lutz P ^a   Kegel, Thomas ^a   Kantelhardt, Eva J ^a   Grothey, Axel ^a,c   Große, Regina ^a   Strauss, Hans Georg ^a   KoelbL , Heinz ^a,d   Thomssen, Christoph ^a   SchmolL , Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Krankenhaus St Elisabeth und St Barbara   (Germany)

^c Mayo Clinic College of Medicine   (United States)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Docetaxel; Gemcitabine; Ovarian cancer; Oxaliplatin; Platinum refractory

Indexed keywords

DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN; PACLITAXEL;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESISTANCE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73349125071     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181b62f38     Document Type: Article

References (56)

1. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998;25:340-348.
2. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006;60:159-179.
3. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000;5:26-35.
4. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195-208.
5. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-2106.
6. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707.
7. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1996;14:2546-2551.
8. Bodurka DC, Levenback C, Wolf JK, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003;21:291-297.
9. Boehmer C, Jaeger W. Capecitabine in treatment of platinum-resistant recurrent ovarian cancer. Anticancer Res. 2002;22:439-443.
10. Chollet P, Bensmaine MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol. 1996;7:1065-1070.
11. D'Agostino G, Amant F, Berteloot P, et al. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 2003;88:266-269.
12. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8.
13. Herzog TJ. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist. 2002;7:3-10.
14. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002;20:2365-2369.
15. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130-135.
16. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405-410.
17. Sorensen P, Hoyer M, Jakobsen A, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81:58-62.
18. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18:3093-3100.
19. Berkenblit A, Seiden MV, Matulonis UA, et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004;95:624-631.
20. Kushner DM, Connor JP, Sanchez F, et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 2007;105:358-364.
21. Strauss HG, Henze A, Teichmann A, et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol. 2007;104:612-616.
22. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994;12:1458-1467.
23. von Minckwitz G, Bauknecht T, Visseren-Grul CM, et al. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10:853-855.
24. Aapro MS, Martin C, Hatty S. GemcitabineVa safety review. Anticancer Drugs. 1998;9:191-201.
25. Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27:258-262.
26. Dieras V, Bougnoux P, Petit T, et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin T taxane-pretreated ovarian cancer patients. Ann Oncol. 2002;13:258-266.
27. Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol. 2000;18: 1193-1202.
28. Faivre S, Kalla S, Cvitkovic E, et al. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol. 1999;10:1125-1128.
29. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990;25: 299-303.
30. Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22:1706-1712.
31. Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist. 2007;12:999-1006.
32. Markman M. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist. 2007;12:186-190.
33. Peters GJ, van der Wilt CL, van Moorsel CJ, et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther. 2000;87:227-253.
34. Robinson BW, Ostruszka L, Im MM, et al. Promising combination therapies with gemcitabine. Semin Oncol. 2004;31:2-12.
35. Voigt W, Kegel T, Weiss M, et al. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol. 2005;131:585-590.
36. Wunderlich D, Buechele T, Zamoryn R, et al. Biweekly docetaxel (DOC), gemcitabine (GEM) and oxaliplatin (LOHP) in pretreated patients with solid tumors. Results of a phase I study. Proc Am Soc Clin Oncol. 2000;19. Abstract 862.
37. Bridgewater JA, Nelstrop AE, Rustin GJ, et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999;17:501-508.
38. Micha JP, Goldstein BH, Rettenmaier MA, et al. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol. 2004; 94:719-724.
39. Ferrandina G, Ludovisi M, De Vincenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol. 2007;18:1348-1353.
40. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol. 2007;25: 4028-4029.
41. Gonzalez-Martin AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005;16: 749-755.
42. Markman M. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials. Gynecol Oncol. 2007;106:279-281.
43. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25: 2811-2818.
44. Markman M, Zanotti K, Webster K, et al. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol. 2003;91:573-576.
45. Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436-440.
46. Tinker AV, Gebski V, Fitzharris B, et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxelVANZGOG 02-01. Gynecol Oncol. 2007;104: 647-653.
47. Polyzos A, Kosmas C, Toufexi H, et al. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res. 2005;25:3559-3564.
48. Harnett P, Buck M, Beale P, et al. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer. 2007;17:359-366.
49. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol. 2004;95:165-172.
50. Nicoletto MO, Falci C, Pianalto D, et al. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol. 2006;100:318-323.
51. Recchia F, Saggio G, Amiconi G, et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecol Oncol. 2007;106:164-169.
52. Valerio MR, Tagliaferri P, Raspagliesi F, et al. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer. 2006;16:79-85.
53. Viens P, Petit T, Yovine A, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol. 2006;17:429-436.
54. Markman M, Liu PY, Rothenberg ML, et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006;24: 1454-1458. (Pubitemid 46622013)
55. Gronlund B, Hogdall C, Hilden J, et al. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol. 2004;22:4051-4058.
56. Markman M. Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data. Oncology. 2006; 71:309-311.